Agios Pharmaceuticals Inc stock is traded at $31.76, with a volume of 497,039. It is down -3.23% in the last 24 hours and up +5.13% over the past month. Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Previous Close:
$32.82
Open:
$32.56
24h Volume:
497,039
Relative Volume:
0.35
Market Cap:
$1.90B
Revenue:
$66.05M
Net Income/Loss:
-$422.60M
P/E Ratio:
-
EPS:
-$7.25
Net Cash Flow:
-$384.73M
1W Performance:
+7.99%
1M Performance:
+5.13%
6M Performance:
+10.39%
1Y Performance:
-25.34%
1-Day Range:
$31.56$32.76
1-Week Range:
$28.93$33.12
52-Week Range:
$22.24$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Name
Agios Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
617-649-8600Address
88 SIDNEY STREET, CAMBRIDGE, MA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS